Liminatus Pharma, Inc. (LIMN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Liminatus Pharma, Inc. (LIMN) closed at USD 3.25 on 2026-10-14, a change of -95.4 % over the past year, with a market capitalization of USD 4.31M.

Liminatus Pharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Liminatus Pharma, Inc. key figures

Previous close

USD 3.25 (2026-10-14)

1-year change

-95.4 %

Market cap

USD 4.31M

Enterprise value

USD 2.74M

P/E ratio (trailing)

-0.15

P/E ratio (forward)

n/a

EPS (trailing)

-21.46

EPS (forward)

n/a

PEG ratio

n/a

Price to book

11.93

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.62

Employees

1

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Liminatus Pharma, Inc. and compare it with other stocks.